The Presence of Diabetes Mellitus or Pre-diabetes Mellitus Increases Mortality from Heart Disease in a Taiwanese Population: A 10-year Follow-Up Study.

BACKGROUND: We evaluated hyperglycemia-associated mortality in the Taiwanese population by conducting a 10-year retrospective cohort study. METHODS: From 2007 to 2017, all participants, regardless of their age or underlying diseases, were identified at a Health Screening Center in Taiwan. Overall, 114,534 participants were included in the analysis. They were classified into three subgroups according to glycemia and smoking status by combining survival for data analysis. RESULTS: The mean follow-up time, age, and body mass index (BMI) were 8.14 ± 2.22 years, 40.95 ± 12.14 years, and 23.24 ± 3.65 kg/m2, respectively. The cumulative death rate increased from 0.9% in the normal fasting blood glucose(FBG) subgroup to approximately 6% in the diabetes FBG subgroup. After adjusting for age, gender, BMI, high-density lipoprotein, triglycerides, waist circumference(WC), and smoking status, the hazard ratio (HR) for all-cause, cancer, and heart disease mortality in the diabetes mellitus(DM) subgroup was 1.560, 1.381, and 1.828, respectively.HR was 0.989 in all-cause, 0.940 in cancer, and 1.326 in heart disease in the pre-DM subgroup. CONCLUSION: Being tested for pre-DM is related to a higher risk of death from heart disease in the Taiwanese population at baseline. Therefore, cardiovascular risk must be actively measured among diabetes patients every visit.

Risk of New-onset Stroke in Patients with Type 2 Diabetes with Chronic Kidney Disease on Sodium-glucose Co-transporter-2 Inhibitor Users.

Clinical studies have investigated the effects of using sodium-glucose co-transporter-2 (SGLT2) inhibitors on the development of new-onset stroke (NOS) in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), but the findings are inconsistent. This study aimed to examine the association between the use of SGLT2 inhibitors and NOS risk in patients with T2D and CKD. We conducted a nationwide retrospective cohort study using data from the Taiwan Health Insurance Review and Assessment Service database for the years 2004 to 2019. The primary outcome was the risk of incident stroke, which was estimated using hazard ratios (HRs) and 95% confidence intervals (CIs). We used multiple Cox regression modeling to analyze the association between SGLT2 inhibitor use and the risk of stroke in patients with T2D and CKD. In a cohort of 113,710 patients with T2D and CKD who were using SGLT2 inhibitors and 227,420 patients with T2D and CKD who were not using SGLT2 inhibitors, after applying a 1:2 sex- and age-matching strategy, 2,842 and 7,169 NOS events were recorded, respectively. The event rate per 10,000 person-months was 10.60 (95% CI 10.21 to 11.03) for SGLT2 inhibitor users and 13.71 (13.39-14.03) for non-SGLT2 inhibitor users. After adjusting for the index year, sex, age, comorbidities, and concurrent medication, there was a decreased risk of NOS for SGLT2 inhibitor users (adjusted HR 0.80; 95% CI 0.77-0.84) compared with non-SGLT2 inhibitor users. The sensitivity test for the propensity score 1:1-matched analyses showed similar results (adjusted HR 0.80; 95% CI 0.76-0.84). The type of SGLT2 inhibitor subgroup analysis for incident stroke showed consistent results. We concluded that the use of SGLT2 inhibitors in patients with T2D and CKD was associated with significantly low rates of NOS. The significantly low rates of NOS in patients with T2D and CKD were greater among females and less than 50 years patients.

Risk of New-Onset Dementia in Patients with Chronic Kidney Disease on Statin Users: A Population-Based Cohort Study.

Patients with chronic kidney disease (CKD) are at a higher risk for developing dementia than the general population. Clinical studies have investigated the effects of statin use on new-onset dementia (NOD) in patients with CKD; however, the findings are inconsistent. This study examines the association between the use of statins and NOD in patients with CKD. We conducted a nationwide retrospective cohort study using the Taiwan Health Insurance Review and Assessment Service database (2003-2016). The primary outcome assessed the risk of incident dementia by estimating the hazard ratios and 95% confidence intervals. Therefore, multiple Cox regression models were conducted to analyse the association between statin use and NOD in patients with CKD. There were 24,090 participants with statin use and 28,049 participants without statin use in patients with new-diagnosed CKD; the NOD event was 1390 and 1608, respectively. There was a trend of reduction association between statin users and NOD events after adjusted sex, age, comorbidities, and concurrent medication (adjusted HR 0.93, 95% CI 0.87 to 1.00) in the 14 years of the follow-up. Sensitivity test for the propensity score 1:1 matched analyses showed similar results (adjusted HR 0.91, 95% CI 0.81 to 1.02). The subgroup analysis also identified the use of statins as having a trend against developing NOD in patients with hypertension. In conclusion, statin therapy may effectively reduce the risk of NOD in patients with CKD. More studies are needed to credibly evaluate the effects of statin therapy on the prevention of NOD in patients with CKD.

Potential risk quantification from multiple biological factors via the inverse problem algorithm as an artificial intelligence tool in clinical diagnosis.

BACKGROUND: The inverse problem algorithm (IPA) uses mathematical calculations to estimate the expectation value of a specific index according to patient risk factor groups. The contributions of particular risk factors or their cross-interactions can be evaluated and ranked by their importance. OBJECTIVE: This paper quantified the potential risks from multiple biological factors by integrated case studies in clinical diagnosis via the IPA technique. Acting as artificial intelligence field component, this technique constructs a quantified expectation value from multiple patients' biological index series, e.g., the optimal trigger timing for CTA, a particular drug in blood concentration data, the risk for patients with clinical syndromes. METHODS: Common biological indices such as age, body surface area, mean artery pressure, and others are treated as risk factors upon their normalization to the range from -1.0 to +1.0, with a non-dimensional zero point 0.0 corresponding to the average risk factor index. The patients' quantified indices are re-arranged into a large data matrix. Next, the inverse and column matrices of the compromised numerical solution are constructed. RESULTS: This paper discusses quasi-Newton and Rosenbrock analyses performed via the STATISTICA program to solve the above inverse problem, yielding the specific expectation value in the form of a multiple-term nonlinear semi-empirical equation. The extensive background, including six previous publications of these authors' team on IPA, was comprehensively re-addressed and scrutinized, focusing on limitations, stumbling blocks, and validity range of the IPA approach as applied to various tasks of preventive medicine. Other key contributions of this study are detailed estimations of the effect of risk factors' coupling/cross-interactions on the IPA computations and the convergence rate of the derived semi-empirical equation viz. the final constant term. CONCLUSION: The main findings and practical recommendations are considered useful for preventive medicine tasks concerning potential risks of patients with various clinical syndromes.

Quantitative Prediction of SYNTAX Score for Cardiovascular Artery Disease Patients via the Inverse Problem Algorithm Technique as Artificial Intelligence Assessment in Diagnostics.

The quantitative prediction of the SYNTAX score for cardiovascular artery disease patients using the inverse problem algorithm (IPA) technique in artificial intelligence was explored in this study. A 29-term semi-empirical formula was defined according to seven risk factors: (1) age, (2) mean arterial pressure, (3) body surface area, (4) pre-prandial blood glucose, (5) low-density-lipoprotein cholesterol, (6) Troponin I, and (7) C-reactive protein. Then, the formula was computed via the STATISTICA 7.0 program to obtain a compromised solution for a 405-patient dataset with a specific loss function [actual-predicted]2 as low as 3.177, whereas 0.0 implies a 100% match between the prediction and observation via "the lower, the better" principle. The IPA technique first created a data matrix [405 × 29] from the included patients' data and then attempted to derive a compromised solution of the column matrix of 29-term coefficients [29 × 1]. The correlation coefficient, r2, of the regression line for the actual versus predicted SYNTAX score was 0.8958, showing a high coincidence among the dataset. The follow-up verification based on another 105 patients' data from the same group also had a high correlation coefficient of r2 = 0.8304. Nevertheless, the verified group's low derived average AT (agreement) (ATavg = 0.308 ± 0.193) also revealed a slight deviation between the theoretical prediction from the STATISTICA 7.0 program and the grades assigned by clinical cardiologists or interventionists. The predicted SYNTAX scores were compared with earlier reported findings based on a single-factor statistical analysis or scanned images obtained by sonography or cardiac catheterization. Cardiologists can obtain the SYNTAX score from the semi-empirical formula for an instant referral before performing a cardiac examination.

Relationships between Alcohol Use, Musculoskeletal Pain, and Work-Related Burnout.

Background and Objectives: Burnout affects approximately half of all nurses, physicians, and other clinicians. Alcohol use may impair performance in work-related tasks, leading to decreased productivity and morale. The present study's aim was to determine whether a causal relationship existed between alcohol use, work-related burnout (WB), and musculoskeletal pain. Materials and Methods: A total of 1633 members from a hospital affiliated with a medical university in Taichung, Taiwan, completed questionnaires in 2021, where 1615 questionnaires were declared valid. Questionnaires were used to obtain information on basic demographic variables, and the Nordic Musculoskeletal Questionnaire and Copenhagen Burnout Inventory were used. Statistical analyses were performed using SAS Enterprise Guide 6.1 software, and significance was set at p < 0.05. Results: Work experience, being married, parenthood, leisure activities with family and friends, and regular weekly exercise were negatively associated with WB. In addition, overtime work, irregular and regular shift work, the physician and nurse medical profession, chronic disease (heart disease, diabetes, etc.), neck and both shoulders pain (NBSP), both ankles pain (BAP), and alcohol use frequency (AUF) were positively associated with WB. NBSP could explain the residual effect of AUF on WB. AUF was determined to mediate the relationship between NBSP and WB. In addition, NBSP was found to mediate the relationship between AUF and WB. Conclusions: The individuals who used alcohol to cope with NBSP or those with NBSP who often consumed alcohol had worsened WB due to a vicious circle of musculoskeletal pain and alcohol use. Therefore, medical staff should not consider alcohol use as an option to reduce burnout.

Sodium-glucose co-transporter-2 inhibitors reduce the risk of new-onset stroke in patients with type 2 diabetes: A population-based cohort study.

Background: Epidemiological evidence suggests the association of diabetes with an increased risk of stroke. Clinical studies have investigated the effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on new-onset stroke (NOS), but the results are inconsistent. Objectives: To determine the association between the use of SGLT2 inhibitors and NOS in patients with type 2 diabetes mellitus (DM). Methods: We conducted a retrospective longitudinal cohort study based on the Taiwan Health Insurance Review and Assessment Service database (2016-2019). The primary outcome of the assessment was the risk of incident stroke by estimating hazard ratios (HRs) and 95% confidence intervals (CIs). Multiple Cox regression was applied to estimate the adjusted HR of NOS. Subgroup analysis was also conducted. Results: Among the 232,101 eligible patients with type 2 DM aged ≥ 20 years, SGLT2-inhibitor users were compared with non-SGLT2-inhibitor users based on age, sex, and the duration of type 2 DM matching at a ratio of 1:2. The event rate per 10 000 person-months was 9.20 (95% CI 8.95 to 9.45) for SGLT2-inhibitor users and 10.5(10.3-10.6) for non-SGLT2-inhibitor users. There was a decreased risk of NOS for SGLT2-inhibitor users (adjusted HR 0.85, 95% CI 0.82-0.88) compared with non-SGLT2-inhibitor users. Results for the propensity score-matched analyses showed similar results (adjusted HR 0.87, 95% CI 0.84-0.91 for both SGLT2-inhibitor users and non-SGLT2-inhibitor users). Conclusion: The risk of developing NOS was lower in patients with SGLT2-inhibitor users than in non-SGLT2-inhibitor users. The decreased risk of NOS in patients with type 2 DM was greater among patients with concurrent use of statins, biguanides, thiazolidinediones, and glucagon-like peptide-1 receptor agonists. We, therefore, suggest that the long-term use of SGLT2 inhibitors may help reduce the incidence of NOS in patients with type 2 DM.

The Association between Serum Testosterone and Hyperuricemia in Males.

Gout is a common systemic inflammatory disease with a male predominance. This study aimed to determine the relationship between serum total testosterone level and hyperuricemia. Data on 1899 men, collected from 2007 to 2017, were included in the analysis. Serum testosterone and urate (SU) were measured on enrolment. The primary endpoints were SU levels ≥ 7 mg/dL and ≥9 mg/dL. On enrolment, participants had a mean age of 45.6 years and mean total testosterone and SU levels of 510 ng/dL and 6.6 mg/dL, respectively. The mean total testosterone levels were 533 and 470 ng/dL in patients with SU levels < 7 mg/dL and ≥7 mg/dL, respectively (p < 0.001); and 515 and 425 ng/dL in patients with SU levels < 9 mg/dL and ≥9 mg/dL, respectively (p < 0.001). After adjusting for age, body mass index, creatinine, serum lipid, fasting blood glucose, systolic blood pressure, and diastolic blood pressure, low testosterone level (<400 ng/dL) was significantly associated with an SU level ≥ 7 mg/dL (hazard ratio: 1.182, 95% confidence interval: 1.005−1.39) and ≥9 mg/dL (hazard ratio: 1.905, 95% confidence interval: 1.239−2.928). In men, a low testosterone level may be associated with an increased risk of hyperuricemia.

Exposure to Proton Pump Inhibitors and the Risk of Incident Asthma in Patients with Coronary Artery Diseases: A Population-Based Cohort Study.

We aimed to determine the association between proton pump inhibitor (PPI) use and incident asthma in patients with coronary artery disease (CAD). This nationwide cohort study collected claims data from the Taiwanese Bureau of National Health Insurance from 2004 to 2013. The primary outcome, i.e., the risk of incident asthma, was assessed by estimating hazard ratios (HRs) and 95% confidence intervals (CIs). The adjusted HR of asthma development was estimated using the Cox regression model. Sensitivity and subgroup analyses were also conducted. A total of 8894 PPI users and 12,684 H2-receptor antagonist (H2RA) users were included in patients with CAD. Compared with H2RA use, an increased risk of incident asthma was found between PPI use and the risk of incident asthma in patients with CAD after adjusting for sex, age, urbanization, and low income (HR: 1.41; 95% CI: 1.04-1.89). The sensitivity analysis results were consistent with the main analysis results. However, the subgroup analysis revealed no association of incident asthma in patients with diabetes mellitus, hyperlipidemia, stroke, allergic rhinitis, pneumonia, cancer, or depression in the PPI group compared with those in the H2RA group. In conclusion, PPI use increased the risk of asthma development in patients with CAD.

Optimizing cardiac CT angiography minimum detectable difference via Taguchi's dynamic algorithm, a V-shaped line gauge, and three PMMA phantoms.

BACKGROUND: Radiologists widely use the minimum detectable difference (MDD) concept for inspecting the imaging quality and quantify the spatial resolution of scans. OBJECTIVE: This study adopted Taguchi's dynamic algorithm to optimize the MDD of cardiac CT angiography (CTA) using a V-shaped line gauge and three PMMA phantoms (50, 70, and 90 kg). METHODS: The phantoms were customized in compliance with the ICRU-48 report, whereas the V-shaped line gauge was indigenous to solidify the cardiac CTA scan image quality by two adjacent peaks along the V-shaped slit. Accordingly, the six factors A-F assigned in this study were A (kVp), B (mAs), C (CT pitch), D (FOV), E (iDose), and F (reconstruction filter). Since each factor could have two or three levels, eighteen groups of factor combinations were organized according to Taguchi's dynamic algorithm. Three welltrained radiologists ranked the CTA scan images three times for three different phantoms. Thus, 27 (3 × 3 × 3) ranked scores were summed and averaged to imply the integrated performance of one specific group, and eventually, 18 groups of CTA scan images were analyzed. The unique signal-to-noise ratio (S/N, dB) and sensitivity in the dynamic algorithm were calculated to reveal the true contribution of assigned factors and clarify the situation in routine CTA diagnosis. RESULTS: Minimizing the cross-interactions among factors, the optimal factor combination was found to be as follows: A (100 kVp), B (600 mAs), C (pitch 0.200 mm), D (FOV 280 mm), E (iDose 5), and F (filter XCA). The respective MDD values were 2.15, 2.32, and 1.87 mm for 50, 70, and 90 kg phantoms, respectively. The MDD of the 90 kg phantom had the most precise spatial resolution, while that of the 70 kg phantom was the worst. CONCLUSION: The Taguchi static and dynamic optimization algorithms were compared, and the latter's superiority was substantiated.

Gender- and age-related differences of statin use on incident dementia in patients with rheumatoid arthritis: a Nationwide population-based cohort study.

BACKGROUND: Some observational studies have found a significant association between the use of statin and a reduced risk of dementia. However, the results of these studies are unclear in patients with rheumatoid arthritis (RA). This study is to determine the association between the use of statins and the incidence of dementia according to sex and age-related differences in patients with RA. METHODS: We conducted a nationwide retrospective cohort study using the Taiwan Health Insurance Review and Assessment Service database (2003-2016). The primary outcome assessed was the risk of dementia by estimating hazard ratios (HRs) and 95% confidence intervals (CIs). Multiple Cox regression was used to estimate the adjusted hazard ratio of new-onset dementia. Subgroup analysis was also conducted. RESULTS: Among the 264,036 eligible patients with RA aged > 40 years, statin users were compared with non-statin users by propensity score matching at a ratio of 1:1 (25,764 in each group). However, no association was found between the use of statins and the risk of new-onset dementia (NOD) in patients with RA (HR: 1.01; 95% CI: 0.97-1.06). The subgroup analysis identified the use of statin as having a protective effect against developing NOD in male and older patients. CONCLUSION: No association was observed between the use of a statin and the risk of NOD in patients with RA, including patients of both genders and aged 40-60 years, but these parameters were affected by gender and age. The decreased risk of NOD in patients with RA was greater among older male patients. Use of a statin in older male (> 60 years) patients with RA may be needed in clinical practice to prevent dementia.

Cardiovascular Protection of Hydroxychloroquine in Patients with Sjögren's Syndrome.

Sjögren's syndrome (SS) is a chronic systemic inflammation disease with clinical presentation of dry eye, dry mouth, and polyarthralgia. Active inflammation is associated with an increased risk of associated arterial stiffness or subclinical atherosclerosis-related cardiovascular events. We used the longitudinal health insurance database of Taiwan, which includes one million participants, to evaluate the relationship between the clinical medication of hydroxychloroquine (HCQ) and the development of coronary artery disease (CAD). In total, 1674 patients with SS receiving HCQ medication were included after exclusion for previous CAD. Altogether, 1142 SS patients were included for evaluation after follow-up for more than one year. After adjusting for age, gender, medications, and chronic comorbidities, a significantly decreased hazard ratio (HR) for developing CAD was found among SS patients with higher medication possession ratio (MPR) of HCQ (HR = 0.49, 95% confidence interval, CI: 0.26-0.94) when compared with low MPR of HCQ. A low HR for CAD was observed in SS patients with a high cumulative dose of at least 100,267 mg of HCQ (HR = 0.25, 95% CI: 0.09-0.66). Long-term HCQ therapy may decrease the HR of CAD in SS patients. The significant cardiovascular protective effect of HCQ therapy was observed in our study.

Estimation and clinical verification of the effective and skin doses for pediatric and adult patients undergoing the cardiac interventional examination using five PMMA phantoms and TLD/ionization chamber technique.

BACKGROUND: Effective and skin doses gain much attention since the cardiac catheterization laboratory (CCL) is a place where both patients and medical staff are exposed to X-ray or fluoroscopy environment and gain a cumulative dose during the cardiac interventional procedure. OBJECTIVE: These doses for pediatric and adult patients undergone cardiac interventional examination using five PMMA phantoms and thermoluminescence dosimeter (TLD)/ionization chamber technique were estimated in this work with the further clinical verification. METHODS: Five PMMA phantoms (10, 30, 50, 70, and 90 kg) were customized to represent baby, child, adult female, adult male, and overweight adult (by Asian complexion standards), respectively, in accordance with the ICRU-48 report. Each phantom could be disassembled into 31 plates to insert TLD chips for measuring X-ray exposed dose or assisted with an auxiliary plate to insert high-sensitivity ionization chamber for surveying low-energy fluoroscopy dose. RESULTS: The data acquired from five phantoms were integrated into four semi-empirical formulas, in order to fit the binary quadratic form "Dose = A⋅BMI2+B⋅DAP2+C⋅BMI+ D⋅DAP+E". The latter linked the X-ray and fluoroscopy effective/skin doses, respectively, with a high coefficient of determination R2(from 0.888 to 0.986). CONCLUSIONS: The model refinement with DAP share adjustment is envisaged.

Survival rate prediction of breast cancer patients of 0-IV stages with and without radiotherapy via a revised Taylor series expansion algorithm: A population-based study in Taiwan.

BACKGROUND: The morbidity of breast cancer has continuously achieved a global topicality. In particular, during the last decade several ten thousand female adults in Taiwan have been confirmed as breast cancer patients. OBJECTIVE: To predict the survival rate of breast cancer patients at various (0-IV) stages and provide efficient assessment of proposed radiotherapy for patients. METHODS: The prediction algorithm proposed is based on the revised hit and target model and implies the application of Taylor series expansion to the population-based survey dataset. The proposed algorithm features a specific function comprising a single simple exponential term exp⁡(-α⁢t) to imply the fundamental degradation of patient's health multiplied by an additional term P⁢(α⁢t), which specifies the recovery effect of a particular therapy. RESULTS: Its calculated values for breast cancer patients who undergone radiotherapy at different stages 0-IV were {0.0029, 0.0066, 0.0178, 0.0475, 0.1785} yr-1, respectively, while those for corresponding groups of patients with no radiotherapy were assessed as {0.0072, 0.0137, 0.0264, 0.0913, 0.2425} yr-1. CONCLUSIONS: The revised algorithm successfully interpreted the breast cancer patients' survival rate at stages 0-IV and evaluated the necessity of radiotherapy for patients at various stages as well.

Resveratrol increases stem cell function in the treatment of damaged pancreas.

Pancreatic damage results in insufficient insulin secretion, leading to type 1 diabetes. Stem cell-based therapy has recently shown potential in the treatment of type 1 diabetes. Resveratrol supplementation has demonstrated a beneficial effect in treating diabetes. This study investigates if adipose-derived stem cells (ADSC), preconditioned with resveratrol, show better effects on experimental diabetic animals. Wistar rats were randomly divided into four groups including sham (normal rats), DM (diabetic rats induced by SZT injection), DM+ADSC (DM rats with receiving autologous ADSC transplantation) and DM+R-ADSC (DM rats receiving resveratrol preconditioned ADSC). The experimental results show that SZT induced pancreatic damage (DM group), including reduction of islet size, fibrosis pathway activation, survival signaling suppression, and apoptotic pathway expression, lead to serum glucose elevation. Autologous ADSC (DM+ADSC group) transplantation shows improvement in the above observations in DM rats. Furthermore, ADSC precondition with resveratrol (DM+R-ADSC group) reveals significant improvement in the above pathological observations over both DM and DM+ADSC groups. We found that ADSC precondition with resveratrol increases the survival marker p-Akt expression, leading to enhanced ADSC viability. This study suggests that ADSC precondition with resveratrol shows potential in the treatment of patients with type 1 DM.

Semi-quantification of the minimum detectable difference of imaging quality of gamma camera SPET for four radionuclides via an innovative PMMA phantom with a V-shaped slit: interpretation of a feasibility study.

OBJECTIVE: An indigenous polymethyl metacrylate (PMMA) phantom with a V-shaped slit and a correlated technique for semi-quantifying the minimum detectable difference (MDD) of single photon emission tomography (SPET) via gamma camera scanning are proposed and validated using four radionuclides. MATERIALS AND METHODS: Radio-actinide solutions of gallium-67 (67Ga), technetium-99m (99mTc), iodine-131 (131I) and thallium-201 (201Tl) were diluted to 11c.c. and thoroughly injected into the continuous zig zag slit of the PMMA phantom. Either depth or edge of the slit between two lines of the V-shape was customized from deep or wide to change into shallow or narrow gradually. Thus, the quantified MDD could be easily evaluated, according to the revised Student's t-test evaluation. The revised Student's t-test was calculated by both full width at half maximum (FWHM) and edge width between two adjacent peaks that were acquired from the original data matrix of SPET. The derived MDD was indicated as for radionuclide, depth, width in mm: For 67Ga, 2.9, 2.13, for 99mTc, 2.5, 0.66, for 131I, 4.7, 2.38 and for 201Tl, 3.3, 2.00, respectively. RESULTS: Technetium-99m had the highest and 131I had the lowest MDD among the four radionuclides. Furthermore, two adjacent peaks of 67Ga could be easily identified with fewer counts than for 201Tl (depth, 2.9 vs. 3.3mm), but its MDD was poorer (width: 2.13 vs.2.00mm). The revised Student's t-test analysis proved to be an acceptable technique for the MDD identification. CONCLUSION: The proposed new combination of PMMA phantom with a V-slit and the revised Student's t-test proved to be instrumental in the MDD of SPET optimization analysis.

Tumorous imaginal disc 1 (TID1) inhibits isoproterenol-induced cardiac hypertrophy and apoptosis by regulating c-terminus of hsc70-interacting protein (CHIP) mediated degradation of Gαs.

Dilated cardiomyopathy (DCM) is the most common form of non-ischemic cardiomyopathy. It is characterized by ventricular chamber dilation, and myocyte hypertrophy. Human tumorous imaginal disc 1 (Tid1), a chaperone protein and response to regulate number of signaling molecules in the mitochondria or cytosol. Tid1 also plays a major role in preventing DCM; however, the role of Tid1 in isoproterenol (ISO)-induced cardiac apoptosis and hypertrophy remains unclear. H9c2 cells were pretreated Tid1 before ISO-induced hypertrophy and apoptosis and then evaluated by IHC, TUNEL assay, IFC, Co-IP, and Western blot. From the IHC experiment, we found that Tid1 proteins were increased in tissues from different stages of human myocardial infarction. Using H9c2 cardiomyoblast cells we found that Tid1 was decreased by ISO treatment. However, over-expression of Tid1S suppressed NFATc3, BNP and calcineurin protein expression and inhibited NFATc3 nuclear translocation in ISO induced cardiomyoblast cells. On the other hand, Tid1S over-expression activated survival proteins p-AKTser473 and decreased caspase-3 and cytochrome c expression. We also found that overexpression of Tid1 enhanced CHIP expression, and induced CHIP to ubiquitinate Gαs, resulting in increased Gαs degradation. Our study showed that Gαs is a novel substrate of CHIP, and we also found that the Tid1-CHIP complex plays an essential role in inhibiting ISO induced cardiomyoblast hypertrophy and apoptosis.